Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S-1 + oxaliplatin
- Development stage
- Phase 2
- Lead developer
- Taiho Pharmaceutical
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
S-1 + oxaliplatin is a combination chemotherapy regimen used primarily for the treatment of advanced or metastatic gastrointestinal cancers such as gastric and colorectal cancer. S-1 is an oral fluoropyrimidine derivative composed of tegafur (a prodrug of 5-fluorouracil), gimeracil (an inhibitor of dihydropyrimidine dehydrogenase to increase 5-FU bioavailability), and oteracil (to reduce gastrointestinal toxicity). Oxaliplatin is a platinum-based alkylating agent that exerts its antitumor effect by forming DNA crosslinks—both interstrand and intrastrand—thereby inhibiting DNA replication and transcription. The combination leverages the cytotoxic effects of both agents to improve efficacy against rapidly dividing tumor cells[2][3][5][6].
- Brand names
- EloxatinS-1S1S 1
- Other names
- S-1S1S 1l-OHPLOHPoxalatoplatinoxaliplatinum
02
Targets
TS (Thymidylate synthase)DNA
Beyond the preview
Go deeper on S-1 + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on S-1 + oxaliplatin.